Valuation : Becton, Dickinson and Company

Market Cap 48.05B 816B 41.33B 38.99B 35.52B 66.4B 4,594B 67.01B 464B 179B 2,330B 180B 177B 7,402B P/E 2026 *
34x
P/E 2027 * 19x
Enterprise Value 63.94B 1,086B 54.99B 51.88B 47.26B 88.35B 6,113B 89.16B 618B 238B 3,101B 240B 235B 9,849B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 3.15x
Free-Float
73.18%
Yield 2026 *
2.22%
Yield 2027 * 2.26%
1 day+4.31%
3 months+4.31%
6 months-11.66%
Current year-24.08%
Current year 2,498.49
Extreme 2498.49
3,093.03
1 year 2,498.49
Extreme 2498.49
3,535.21
3 years 2,498.49
Extreme 2498.49
4,843.41
5 years 2,498.49
Extreme 2498.49
5,784.37
10 years 2,498.49
Extreme 2498.49
6,405.1
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+4.31%-.--% - - 48.05B
-1.78%-4.99%-20.10%+2.61% 179B
-0.29%-1.59%-0.76%+14.58% 117B
-0.73%-4.82%+8.31%+80.61% 61.25B
-1.92%-6.01%+8.80%+41.11% 50.24B
-1.88%-5.97%-6.37%-33.87% 48.05B
+0.75%-5.80%+11.20%-19.01% 31.89B
-4.88%-11.48% - - 28.42B
+2.17%+0.44%+34.88%-12.44% 24.23B
+0.49%-7.65%-12.44%+4.86% 21.4B
Average -0.13%-5.18%+2.94%+9.81% 62.39B
Weighted average by Cap. -0.02%-4.24%-3.94%+12.66%

Financials

2026 *2027 *
Net sales 19.26B 327B 16.56B 15.63B 14.24B 26.61B 1,841B 26.86B 186B 71.64B 934B 72.33B 70.75B 2,967B 19.69B 334B 16.93B 15.98B 14.55B 27.21B 1,882B 27.45B 190B 73.23B 955B 73.93B 72.32B 3,033B
Net income 1.44B 24.39B 1.24B 1.17B 1.06B 1.99B 137B 2B 13.88B 5.34B 69.67B 5.39B 5.28B 221B 2.34B 39.72B 2.01B 1.9B 1.73B 3.23B 224B 3.26B 22.61B 8.7B 113B 8.79B 8.59B 360B
Net Debt 15.88B 270B 13.66B 12.89B 11.74B 21.95B 1,519B 22.15B 154B 59.08B 770B 59.65B 58.35B 2,447B 13.95B 237B 12B 11.32B 10.31B 19.28B 1,334B 19.45B 135B 51.89B 677B 52.39B 51.25B 2,149B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
176.42USD
Average target price
195.67USD
Spread / Average Target
+10.91%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!